NCT01474434View on ClinicalTrials.gov

Efficacy of LCQ908 on Cardiovascular Risk

PHASE2TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Coronary Artery DiseaseHypertriglyceridemia
Interventions
DRUG

pradigastat (LCQ908)

pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.

DRUG

Placebo

matching placebo tablets

Trial Locations (1)

91105

Novartis Investigative Site, Pasadena

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY